SEOUL, South Korea, Nov. 19, 2025 /PRNewswire/ -- ToolGen (KOSDAQ: 199800; CEO Jong-sang Ryu), a leader in genome editing technology, announced that the United States Patent and Trademark Office has ...
Dublin, Ireland, and Cheshire, UK, 04 September 2024: ERS Genomics Limited (‘ERS’), the CRISPR licensing Company, and Medicines Discovery Catapult (‘MDC’), an independent, not-for-profit drug ...
UC and Broad have been involved in two interferences at the patent office. Interference No. 106,115 was the second interference between UC and Broad over patent rights to CRISPR-Cas9 technology in ...
Announcing a new article publication for Zoonoses journal. As global warming increases, mosquito activity areas are expanding, alongside changes in the natural environment and the misuse of ...
CRISPR Therapeutics AG stock has surged nearly 90% since my Buy call in early May, reaching its highest value since February 2024. The rally builds on the historic approval of Casgevy, a gene editing ...
Hosted on MSN
CRISPR and the Ethics of Human Germline Intervention
Genetic modifications in reproductive cells, such as eggs, sperm, or embryos, are commonly referred to as germline editing and are heritable. 1 CRISPR-Cas 9, which stands for clustered regularly ...
Crispr Therapeutics AG remains a Strong Buy, driven by forthcoming revenue following Casgevy's FDA/EMA approvals and a robust, expanding pipeline targeting high-value indications. CRSP's commercial ...
CRISPR, or Clustered Regularly Interspaced Short Palindromic Repeats, is an advanced technology developed in 2012 that can be used to edit genes. It can be used to find specific DNA sequences inside ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results